Bitropic D3 Dopamine Receptor Selective Compounds as Potential Antipsychotics.

Abstract

Neuropsychiatric disorders represent a substantial social and health care issue. The National Institutes of Health estimates that greater than 2 million adults suffer from neuropsychiatric disorders in the USA. These individuals experience symptoms that can include auditory hallucinations, delusions, unrealistic beliefs and cognitive dysfunction. Although antipsychotic medications are available, suboptimal therapeutic responses are observed for approximately one-third of patients. Therefore, there is still a need to explore new pharmacotherapeutic strategies for the treatment of neuropsychiatric disorders. Many of the medications that are used clinically to treat neuropsychiatric disorders have a pharmacological profile that includes being an antagonist at D2-like (D2, D3 and D4) dopamine receptor subtypes. However, dopamine receptor subtypes are involved in a variety of neuronal circuits that include movement coordination, cognition, emotion, affect, memory and the regulation of prolactin. Consequently, antagonism at D2-like receptors can also contribute to some of the adverse side effects associated with the long-term use of antipsychotics including the a) adverse extrapyramidal symptoms associated with the use of typical antipsychotics and b) metabolic side effects (weight gain, hyperglycemia, increased risk of diabetes mellitus, dyslipidemia and gynecomastia) associated with atypical antipsychotic use. Preclinical studies suggest that D3 versus D2 dopamine receptor selective compounds might represent an alternative strategy for the treatment of the symptoms of schizophrenia. In this review we discuss a) how bitropic Nphenylpiperazine D3 dopamine receptor selective compounds have been developed by modification of the primary (orthosteric) and secondary (allosteric or modulatory) pharmacophores to optimize D3 receptor affinity and D2/D3 binding selectivity ratios and b) the functional selectivity of these compounds. Examples of how these compounds might be modified to develop bivalent ligands capable of interacting with receptor dimers or oligomers are also provided. Preclinical studies using bitropic D3 dopamine receptor selective ligands are also discussed as strategy to pharmacologically dissect the role of the D2 and D3 dopamine receptor subtypes in animal models of neuropsychiatric, neurological and substance abuse disorders. This research has the potential to a) advance the understanding of the role of the D2 and D3 dopamine receptor subtypes in neuropsychiatric disorders and b) lead to new treatment strategies for neuropsychiatric disorders.

• Authors: Robert R Luedtke, Claudia Rangel-Barajas, Mahinder Malik, David E Reichert, R H Mach
• Journal: Current pharmaceutical design (Curr Pharm Des) Vol. 21 Issue 26 Pg. 3700-24 ( 2015) ISSN: 1873-4286 [Electronic] United Arab Emirates
• PMID: 26205291 (Publication Type: Journal Article, Review)

Chemical References

• Antipsychotic Agents
• Piperazines
• Receptors, Dopamine D2
• Receptors, Dopamine D3
• Receptors, G-Protein-Coupled

Topics

• Animals
• Antipsychotic Agents (pharmacology, therapeutic use)
• Humans
• Piperazines (pharmacology)
• Receptors, Dopamine D2 (drug effects, physiology)
• Receptors, Dopamine D3 (drug effects, physiology)
• Receptors, G-Protein-Coupled (drug effects, physiology)
• Schizophrenia (drug therapy, physiopathology)
• Signal Transduction (drug effects)
• Structure-Activity Relationship